ArticleWorld journal of microbiology & biotechnology2023
A marine lipopeptides-producing Bacillus amyloliquefaciens HY2-1 with a broad-spectrum antifungal and antibacterial activity and its fermentation kinetics study.
Article in World journal of microbiology & biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Bacillus-based probiotics and fermented products as alternatives to antibiotic growth promoters in poultry: Current perspectives.Poultry science · 2026Review
- Potential of Bacillus amyloliquefaciens XSZ-1 as a bio-inoculant for enhancing cotton productivity and health in saline-alkali cotton field soil.World journal of microbiology & biotechnology · 2026Article
- In vitro probiotic properties and anti-Vibrio activity of Bacillus subtilis B13 and its ethyl acetate extract.Antonie van Leeuwenhoek · 2026Article
- Evaluation of the inhibitory effect of the cell-free fermentation filtrate ofFrontiers in microbiology · 2026Article
- Natural Products from Marine Microorganisms with Agricultural Applications.Marine drugs · 2025Review
- Identification of an antifungal lipopeptide fromMicrobiology spectrum · 2025Article
- Biosynthesis and yield improvement strategies of fengycin.Archives of microbiology · 2025Review
- Novel Insights into the Nobilamide Family from a Deep-SeaMarine drugs · 2025Article
- Genome and Transcriptome Analysis to Elucidate the Biocontrol Mechanism ofMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antagonistic Bacillus amyloliquefaciens HY2-1 was a marine microbiology that was isolated previously from the seabed silt of Beibu Gulf in China by dual culture with Penicillium digitatum. As a continuous study, the present work focused on evaluating the antimicrobial activity, identifying the produced active components, and revealing the fermentation characteristics of B. amyloliquefaciens HY2-1, respectively. It was found that B. amyloliquefaciens HY2-1 exhibited a broad-spectrum antimicrobial activity against the tested seven phytopathogenic fungi and five pathogenic bacteria by producing Bacillus lipopeptides such as fengycin A (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.